Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Veliparib and Berzosertib with Cisplatin in Solid Tumors
NCT02723864Phase 1Completed
- Sponsor
- National Cancer Institute
- Start
- Aug 2017
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of veliparib and berzosertib in solid tumor, sponsored by National Cancer Institute. Primary endpoint: Number of Participants With Worst Grade 2 or Higher Adverse Events Occurring in >5% of Participants at Least Possibly Related to Study Drugs. Started Aug 2017; status: completed.
02
Drugs
veliparibberzosertib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02723864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02723864.